<p>Actinium Pharmaceuticals，這家醫療行業公司，昨天被華爾街分析師重新評估。Maxim Group 的分析師 Jason McCarthy 維持了對該股票的買入評級，並設定了 5.00 美元的目標價。</p>
<h3>在 TipRanks Premium 上享受 50% 的折扣，信心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>Jason McCarthy 給予買入評級是基於與 Actinium Pharmaceuticals 的有前景的發展相關的多種因素。Actinium 的 ATNM-400 是一種利用鈾-225 的靶向放射治療，已在多種癌症類型中顯示出顯著的抗腫瘤活性，包括乳腺癌、肺癌和前列腺癌。這包括在耐藥模型中的有效性，使 Actinium 在放射藥物和抗體藥物結合物領域中處於領先地位。</p>
<p>此外，該公司資本充足，財務狀況良好，截至 2025 年第三季度末擁有 5340 萬美元的現金，為持續發展提供了堅實的基礎。ATNM-400 的未披露靶點與腫瘤進展和耐藥性相關，為未來的增長增添了一層神秘和潛力。這些因素共同支撐了 McCarthy 對 Actinium Pharmaceuticals 的樂觀展望和買入評級。</p>
<p>McCarthy 覆蓋醫療行業，關注的股票包括 Actinium Pharmaceuticals、Plus Therapeutics 和 SCYNEXIS。根據 TipRanks 的數據，McCarthy 的平均回報率為-7.8%，推薦股票的成功率為 37.42%。</p>
<p>在昨天發佈的另一份報告中，H.C. Wainwright 也重申了對該股票的買入評級，目標價為 4.00 美元。</p>

Actinium制藥

<p>Actinium 製藥獲得了 Maxim Group 分析師 Jason McCarthy 的買入評級，目標價為 5.00 美元，原因是其 ATNM-400 放射治療的有希望進展以及強勁的財務狀況。該公司擁有 5340 萬美元的現金，支持未來的增長。H.C. Wainwright 也重申了買入評級，目標價為 4.00 美元</p>

<p>Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.</p>
<div class="lb-trans"><p>Actinium Pharmaceuticals，這家醫療行業公司，昨天被華爾街分析師重新評估。Maxim Group 的分析師 Jason McCarthy 維持了對該股票的買入評級，並設定了 5.00 美元的目標價。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 的折扣，信心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising developments. Actinium’s ATNM-400, a targeted radiotherapy utilizing Actinium-225, has shown significant anti-tumor activity across various cancer types, including breast, lung, and prostate cancers. This includes effectiveness in treatment-resistant models, which positions Actinium as a leader in the radiopharmaceutical and antibody-drug conjugate sectors.</p>
<div class="lb-trans"><p>Jason McCarthy 給予買入評級是基於與 Actinium Pharmaceuticals 的有前景的發展相關的多種因素。Actinium 的 ATNM-400 是一種利用鈾-225 的靶向放射治療，已在多種癌症類型中顯示出顯著的抗腫瘤活性，包括乳腺癌、肺癌和前列腺癌。這包括在耐藥模型中的有效性，使 Actinium 在放射藥物和抗體藥物結合物領域中處於領先地位。</p>
</div><p>Furthermore, the company is well-capitalized with a strong financial position, having $53.4 million in cash at the end of the third quarter of 2025, providing a solid runway for continued development. The undisclosed target of ATNM-400, which is associated with tumor progression and resistance, adds a layer of intrigue and potential for future growth. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.</p>
<div class="lb-trans"><p>此外，該公司資本充足，財務狀況良好，截至 2025 年第三季度末擁有 5340 萬美元的現金，為持續發展提供了堅實的基礎。ATNM-400 的未披露靶點與腫瘤進展和耐藥性相關，為未來的增長增添了一層神秘和潛力。這些因素共同支撐了 McCarthy 對 Actinium Pharmaceuticals 的樂觀展望和買入評級。</p>
</div><p>McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -7.8% and a 37.42% success rate on recommended stocks.</p>
<div class="lb-trans"><p>McCarthy 覆蓋醫療行業，關注的股票包括 Actinium Pharmaceuticals、Plus Therapeutics 和 SCYNEXIS。根據 TipRanks 的數據，McCarthy 的平均回報率為-7.8%，推薦股票的成功率為 37.42%。</p>
</div><p>In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.</p>
<div class="lb-trans"><p>在昨天發佈的另一份報告中，H.C. Wainwright 也重申了對該股票的買入評級，目標價為 4.00 美元。</p>
</div>

Actinium 製藥：有前景的發展和穩健的財務狀況推動買入評級